See more : Precision System Science Co., Ltd. (PCNEF) Income Statement Analysis – Financial Results
Complete financial analysis of Cryoport, Inc. (CYRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cryoport, Inc., a leading company in the Integrated Freight & Logistics industry within the Industrials sector.
You may be interested
- Saudi Chemical Holding Company (2230.SR) Income Statement Analysis – Financial Results
- Marg Techno-Projects Limited (MTPL.BO) Income Statement Analysis – Financial Results
- W. P. Carey Inc. (WPC) Income Statement Analysis – Financial Results
- Damon Inc. Common Stock (DMN) Income Statement Analysis – Financial Results
- Roma Green Finance Limited Ordinary Shares (ROMA) Income Statement Analysis – Financial Results
Cryoport, Inc. (CYRX)
About Cryoport, Inc.
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 233.26M | 237.28M | 222.61M | 78.70M | 33.94M | 19.63M | 11.95M | 7.68M | 5.88M | 3.94M | 2.66M | 1.10M | 555.64K | 475.50K | 117.96K | 35.12K | 83.56K | 67.10K | 152.30K | 271.43K |
| Cost of Revenue | 133.92M | 133.40M | 126.03M | 42.36M | 16.59M | 9.39M | 5.99M | 4.58M | 3.99M | 2.77M | 2.22M | 1.59M | 1.39M | 1.30M | 717.71K | 546.15K | 386.37K | 176.94K | 315.65K | 499.65K |
| Gross Profit | 99.33M | 103.87M | 96.58M | 36.33M | 17.35M | 10.24M | 5.97M | 3.10M | 1.89M | 1.17M | 436.96K | -487.28K | -836.82K | -827.48K | -599.75K | -511.03K | -302.81K | -109.84K | -163.35K | -228.22K |
| Gross Profit Ratio | 42.59% | 43.78% | 43.38% | 46.17% | 51.12% | 52.18% | 49.91% | 40.39% | 32.14% | 29.70% | 16.43% | -44.28% | -150.61% | -174.02% | -508.46% | -1,454.93% | -362.37% | -163.68% | -107.26% | -84.08% |
| Research & Development | 18.04M | 15.72M | 16.84M | 9.48M | 3.74M | 1.84M | 1.21M | 598.11K | 550.26K | 352.58K | 409.11K | 425.45K | 491.85K | 449.13K | 284.85K | 297.38K | 166.23K | 87.86K | 254.49K | 98.70K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 17.47M | 9.80M | 7.42M | 6.45M | 5.93M | 6.41M | 5.11M | 5.41M | 6.11M | 4.32M | 3.31M | 2.39M | 2.55M | 1.90M | 1.02M | 622.80K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 13.82M | 7.25M | 5.23M | 4.82M | 4.16M | 2.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 146.88M | 120.06M | 97.56M | 56.86M | 31.29M | 17.04M | 12.65M | 11.27M | 10.08M | 6.41M | 5.11M | 5.41M | 6.11M | 4.32M | 3.31M | 2.39M | 2.55M | 1.90M | 1.02M | 622.80K |
| Other Expenses | 49.57M | -5.52M | -2.82M | -929.00K | 772.07K | 77.63K | 14.34K | -6.77K | -9.90K | -4.27K | -13.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -630.00 | -3.00 | 0.00 |
| Operating Expenses | 214.49M | 135.78M | 114.41M | 66.34M | 35.03M | 18.88M | 13.86M | 11.87M | 10.63M | 6.76M | 5.52M | 5.84M | 6.60M | 4.77M | 3.60M | 2.68M | 2.72M | 1.99M | 1.28M | 721.50K |
| Cost & Expenses | 348.41M | 269.18M | 240.44M | 108.71M | 51.62M | 28.27M | 19.85M | 16.44M | 14.62M | 9.53M | 7.74M | 7.42M | 7.99M | 6.07M | 4.32M | 3.23M | 3.10M | 2.16M | 1.59M | 1.22M |
| Interest Income | 0.00 | 8.47M | 3.25M | 761.00K | 784.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.94K | 15.57K | 8.16K | 32.10K | 50.08K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.50M | 6.14M | 4.69M | 2.56M | 1.37M | 69.25K | 15.69K | 139.42K | 1.07M | 1.43M | 784.45K | 72.86K | 527.75K | 618.77K | 7.03M | 2.69M | 1.59M | 228.37K | 80.38K | 85.77K |
| Depreciation & Amortization | 27.49M | 22.77M | 20.25M | 9.87M | 2.42M | 857.94K | 664.83K | 374.20K | 239.23K | 197.94K | 311.59K | 393.96K | 343.03K | 245.48K | 150.09K | 81.98K | 1.34M | 111.22K | 88.75K | 92.60K |
| EBITDA | -66.36M | -6.19M | -248.91M | -20.31M | -14.49M | -8.61M | -7.21M | -13.38M | -8.51M | -5.40M | -18.47M | -5.91M | -6.96M | -5.29M | 1.53M | -13.93M | -2.93M | -1.99M | -1.35M | -857.12K |
| EBITDA Ratio | -28.45% | -15.77% | -9.28% | -39.31% | -49.80% | -43.65% | -65.90% | -109.37% | -148.77% | -142.23% | -706.79% | -538.87% | -1,274.16% | -1,122.18% | -3,424.14% | -8,773.52% | -2,005.44% | -2,958.25% | -887.85% | -315.11% |
| Operating Income | -115.16M | -31.90M | -17.83M | -30.01M | -17.68M | -8.64M | -7.89M | -8.77M | -8.74M | -5.59M | -5.08M | -6.32M | -7.43M | -5.60M | -4.20M | -3.20M | -3.02M | -2.10M | -1.44M | -949.72K |
| Operating Income Ratio | -49.37% | -13.45% | -8.01% | -38.13% | -52.07% | -44.05% | -66.02% | -114.16% | -148.60% | -142.12% | -190.92% | -574.67% | -1,338.05% | -1,177.08% | -3,558.31% | -9,098.32% | -3,613.77% | -3,123.99% | -946.12% | -349.89% |
| Total Other Income/Expenses | 15.81M | -3.19M | -256.01M | -2.73M | -594.90K | -891.03K | -1.36K | -4.34M | -1.08M | -1.43M | -14.49M | -56.38K | -396.65K | -553.60K | -1.45M | -13.51M | -1.54M | -228.37K | -80.38K | -87.59K |
| Income Before Tax | -99.35M | -35.09M | -273.84M | -32.74M | -18.27M | -9.54M | -7.89M | -13.11M | -9.82M | -7.03M | -19.56M | -6.38M | -7.83M | -6.15M | -5.65M | -16.70M | -4.56M | -2.32M | -1.52M | -1.04M |
| Income Before Tax Ratio | -42.59% | -14.79% | -123.02% | -41.60% | -53.83% | -48.59% | -66.03% | -170.70% | -166.89% | -178.52% | -735.50% | -579.79% | -1,409.43% | -1,293.51% | -4,789.89% | -47,555.95% | -5,459.83% | -3,464.31% | -998.90% | -382.17% |
| Income Tax Expense | 239.00K | 2.24M | 1.69M | -45.00K | 61.58K | 19.95K | 5.14K | 5.67K | 3.63K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 800.00 | 800.00 |
| Net Income | -99.59M | -37.33M | -275.53M | -32.69M | -18.33M | -9.56M | -7.90M | -13.11M | -9.82M | -7.03M | -19.57M | -6.38M | -7.83M | -6.15M | -5.65M | -16.71M | -4.56M | -2.33M | -1.52M | -1.04M |
| Net Income Ratio | -42.69% | -15.73% | -123.77% | -41.54% | -54.01% | -48.69% | -66.08% | -170.77% | -166.95% | -178.56% | -735.56% | -579.94% | -1,409.72% | -1,293.84% | -4,791.25% | -47,560.50% | -5,461.75% | -3,466.70% | -999.42% | -382.46% |
| EPS | -2.21 | -0.76 | -6.00 | -0.85 | -0.55 | -0.34 | -0.34 | -0.92 | -1.34 | -1.31 | -4.48 | -1.89 | -3.03 | -5.18 | -12.63 | -45.35 | -12.96 | -8.42 | -5.70 | -6.49 |
| EPS Diluted | -2.21 | -0.76 | -6.00 | -0.85 | -0.55 | -0.34 | -0.34 | -0.92 | -1.34 | -1.31 | -4.48 | -1.89 | -3.03 | -5.18 | -12.63 | -45.35 | -12.96 | -8.42 | -5.70 | -6.49 |
| Weighted Avg Shares Out | 48.74M | 48.99M | 45.93M | 38.58M | 33.39M | 28.21M | 22.96M | 14.20M | 7.34M | 5.37M | 4.37M | 3.37M | 2.59M | 1.19M | 447.59K | 368.34K | 352.15K | 276.39K | 266.97K | 159.95K |
| Weighted Avg Shares Out (Dil) | 48.74M | 48.99M | 45.93M | 38.58M | 33.39M | 28.21M | 22.96M | 14.22M | 7.34M | 5.37M | 4.37M | 3.37M | 2.59M | 1.19M | 447.59K | 368.34K | 352.15K | 276.39K | 266.97K | 159.95K |
The Schall Law Firm Initiates Investigation Into Claims Against Cryoport Inc And Urges Its Shareholders To Contact
LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
The Schall Law Firm Begins Probe Into Allegations Against Cryoport Inc And Encourages Its Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
The Schall Law Firm Initiates Investigation Into Claims Against Cryoport Inc And Urges Its Shareholders To Get In Touch
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations of the securities laws. The investigation focuses on whether the...
Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 300 points on Wednesday.
Cryoport, Inc. (CYRX) Q2 2024 Earnings Call Transcript
Cryoport, Inc. (NASDAQ:CYRX ) Q2 2024 Results Conference Call August 6, 2024 5:00 PM ET Company Participants Todd Fromer - Investor Relations-KCSA Strategic Communications Jerrell Shelton - Chief Executive Officer Mark Sawicki - Chief Scientific Officer Robert Stefanovich - Chief...
CryoPort, Inc. (CYRX) Reports Q2 Loss, Lags Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.42 per share a year ago.
The Schall Law Firm Begins Investigation Into Claims Against Cryoport Inc And Encourages Its Shareholders To Contact
LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
Cryoport Reports Second Quarter 2024 Financial Results
Revenue improved sequentially across all businesses Commercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially A record total of 684 global clinical trials supported as of June 30, 2024 Cost reduction initiatives anticipated to result in approximately...
Cryoport Announces $200 Million Repurchase Program and the Repurchase of $160 Million of Convertible Senior Notes
$200 million repurchase program authorized to repurchase common stock and/or convertible notes Repurchasing approximately $160 million of 0.75% Senior Notes due in 2026 at an 11.5% discount to par value Principal balance reduced to approximately $186.2 million NASHVILLE, Tenn. ,...
Cryoport Incorporated Stockholders Are Encouraged By The Schall Law Firm To Make Contact During The Initiation Of An Allegations Investigation
LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
Source: https://incomestatements.info
Category: Stock Reports